La vendita allo scoperto per Hologic dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Hologic. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Hologic (NASDAQ:HOLX) Azioni, Report sulle vendite allo scoperto

HOLOGIC INC

Hologic

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

AMZN

HOLX

ORCL

Con l&#39;ottimismo che pervade Wall Street, alcuni titoli mostrano promettenti segnali di crescita per l&#39;ultima settimana di gennaio.

5 azioni dell&#39;S&amp;P 500 che potrebbero decollare a fine gennaio

Mizuho analyst Anthony Petrone maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Outperform and raises the price target from $65 to $70.

News

Price Target

Analyst Ratings

Mizuho Maintains Outperform on Hologic, Raises Price Target to $70

Citigroup analyst Patrick Donnelly upgrades Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) from Neutral to Buy and raises the price target from $60 to $80.

Upgrades

Citigroup Upgrades Hologic to Buy, Raises Price Target to $80

In the latest quarter, 6 analysts provided ratings for Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $67.67, with a high estimate of $71.00 and a low estimate of $62.00. This current average has decreased by 8.96% from the previous average price target of $74.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1752012023_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Hologic's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$68.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$65.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$70.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$71.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$62.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hologic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hologic compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Hologic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Hologic's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/HOLX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Hologic analyst ratings.</a>
<h2>Delving into Hologic's Background</h2>
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
<h3>A Deep Dive into Hologic's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3M period, Hologic faced challenges, resulting in a decline of approximately -1.23% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Hologic's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -1.73%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Hologic's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.37%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Hologic's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.2%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Hologic's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.55.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Hologic: 6 Analysts Share Their Views

Evercore ISI Group analyst Vijay Kumar maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a In-Line and raises the price target from $62 to $68.

Evercore ISI Group Maintains In-Line on Hologic, Raises Price Target to $68

Hologic's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NYSE">HOLX</a>) short percent of float has fallen 29.41% since its last report. The company recently reported that it has 5.11 million shares sold short, which is 3.0% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.03 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Hologic Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750784432_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Hologic has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Hologic's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Hologic's peer group average for short interest as a percentage of float is 5.22%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Is the Market Bullish or Bearish on Hologic?

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol class="wp-block-list">
<li>United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) shares jumped 25.45%. Japan&#8217;s Nippon Steel is set to finalize its acquisition of the company at $55 per share, according to <a href="https://www.benzinga.com//node/45622810" target="_blank" rel="noreferrer noopener">sources familiar with the matter</a>.</li>
<li>Unity Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) shares escalated 19.30% after Jefferies analyst Brent Thill upgraded the company from Hold to Buy and raised <a href="https://www.benzinga.com/quote/u/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast from $22 to $29</a>.</li>
<li>Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) shares rose 18.75% after multiple analysts raised their price forecasts on the stock. The company <a href="https://www.benzinga.com//node/45677373" target="_blank" rel="noreferrer noopener">recently raised its FY26 guidance</a>.</li>
<li>BWX Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>) shares upped 16.71% as President Donald Trump signed a suite of executive orders to <a href="https://www.benzinga.com//node/45654523" target="_blank" rel="noreferrer noopener">revive the U.S. nuclear industry</a>.</li>
<li>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) shares increased 14.88% after the company reported better-than-expected first-quarter earnings and analysts <a href="https://www.benzinga.com//node/45695903" target="_blank" rel="noreferrer noopener">raised the price forecast on the stock</a>.</li>
<li>Reddit, Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) stock increased 14.27% after it was named among the <a href="https://www.benzinga.com//node/45679678" target="_blank" rel="noreferrer noopener">additions to the Russell 3000 index</a>.</li>
<li>Hologic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) stock grew 14.12% after private equity firms TPG and Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) recently bid to acquire the company, <a href="https://www.benzinga.com//node/45629538" target="_blank" rel="noreferrer noopener">valuing it at over $16 billion</a>.</li>
<li>Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) stock upped 13.12%, possibly amid overall market strength after President Trump delayed 50% EU tariffs to July.</li>
<li>Heico Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>) shares were up 12.19% after the company reported <a href="https://www.benzinga.com//node/45630872" target="_blank" rel="noreferrer noopener">better-than-expected financial results</a>.</li>
<li>Applovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) stock gained 11.82% last week. It continued upward momentum following <a href="https://www.benzinga.com//node/45543602" target="_blank" rel="noreferrer noopener">strong Q1 earnings</a> and tariff <a href="https://www.benzinga.com//node/45655193" target="_blank" rel="noreferrer noopener">truce tailwinds</a>.</li>
</ol>
Photo via Shutterstock

Large Cap

Movers

BWXT

INTU

RDDT

ULTA

VEEV

United States Steel, Applovin And Ulta Beauty Are Among Top Large-Cap Gainers Last Week (May 26-May 30): Are The Others In Your Portfolio?

<h3 class="wp-block-heading">New On The Block</h3>
<ul class="wp-block-list">
<li>Revolution Beauty is putting itself in the shop window. The UK cosmetics brand has kicked off a formal sale process and is considering funding options as part of a broader strategic review, including a potential sale. Advisors are on board and talks with interested parties have begun. The news comes as CEO Lauren Brindley <a href="https://theindustry.beauty/revolution-beauty-ceo-lauren-brindley-exits/">departs</a> the company. Brindley, who became CEO in September 2023, <a href="https://www.benzinga.com/topic/beauty">accepted a leadership position</a> at Ulta Beauty Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>).</li>
</ul>
<ul class="wp-block-list">
<li>Also for sale: Apryse, a Denver-based document processing software provider, is on the auction block. Thoma Bravo hired Lazard to fetch a buyer willing to pay over $3 billion, according to Reuters.</li>
</ul>
<h3 class="wp-block-heading">Updates From The Block</h3>
<ul class="wp-block-list">
<li>E.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45677382/elf-beauty-buys-hailey-biebers-brand-rhode-for-1-billion-now-shes-richer-than-husband-justin-bieber">just made a billion-dollar bet</a> on lip gloss and blush. The company acquired Hailey Bieber's cosmetics brand, Rhode, for a cool $1 billion. And now Hailey officially out-earns her pop-star husband, Justin. Founded in 2022 and named after her middle name (and stylized with a lowercase "r"), the startup owes its hefty price tag to a Gen Z following and $212 million in sales in just the last year. </li>
<li>Acrisure lands a $2.1 billion investment from Bain Capital at a $32 billion valuation. The Michigan-based insurance giant raised fresh capital and is putting it to work—agreeing to acquire the payroll business of Global Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) for $1.1 billion.</li>
</ul>
<ul class="wp-block-list">
<li>According <a href="https://www.ft.com/content/f4d12c75-1a54-4d8c-8aa6-f863cbdc4aab">to</a> Financial Times, Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) rejected an unsolicited $16 billion takeover bid from Blackstone and TPG. </li>
</ul>
<ul class="wp-block-list">
<li>MBK Partners, Northeast Asia&#8217;s largest private equity firm, is set to <a href="https://asia.nikkei.com/Business/Business-deals/Asian-private-equity-firm-MBK-wins-first-negotiation-rights-for-Makino">acquire</a> Japanese machine tool maker Makino Milling Machine in a deal estimated at over 2 trillion won ($1.75 billion). MBK has secured exclusive negotiation rights, beating out Carlyle Group, and plans to proceed via a tender offer at 11,000 yen per share. The same price was previously offered by Nidec in a hostile takeover attempt in April 2025, which was withdrawn in May due to Makino's resistance. The exact scope of MBK's tender offer hasn't been revealed. MBK will finance the acquisition using its sixth blind fund, launched in 2024. Makino, founded in 1937 and headquartered in Tokyo, is a global leader in precision machine tools. </li>
<li>Private equity firm H.I.G. Capital is set to take over Rentokil's French workwear division for $464 million. </li>
</ul>
<h3 class="wp-block-heading">Off The Block</h3>
<ul class="wp-block-list">
<li>E2open (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>) is no longer for sale. The supply chain software firm just got picked up by Australia's WiseTech Global in a $2.1 billion deal. Shareholders will receive $3.30 a share in cold, hard cash—about 28% more than the stock's pre-announcement price and a whopping 68% premium over the closing stock price on April 30. <a href="https://www.benzinga.com/25/05/45612567/why-e2open-shares-are-trading-higher-by-25-here-are-20-stocks-moving-premarket">E2open&#8217;s shares rose</a> on the heels of the announcement and four <a href="https://www.benzinga.com/insights/analyst-ratings/25/05/45656183/4-analysts-assess-e2open-parent-holdings-what-you-need-to-know">analysts shared their evaluations</a>.</li>
</ul>
<ul class="wp-block-list">
<li>Energy company EOG Resources, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) inked <a href="https://www.benzinga.com/cannabis/25/05/45693631/eog-strikes-5-6b-deal-to-expand-utica-footprint-boosts-dividend#google_vignette">a deal to acquire</a> Encino Acquisition Partners (EAP) for $5.6 billion, including EAP&#8217;s net debt. EOG agreed to pay the sellers, Canada Pension Plan Investment Board (CPP) and Encino Energy, with cash and debt. The purchase price includes $3.5 billion in new debt and $2.1 billion in cash. The company expects the transaction to close in the latter half of 2025, upon clearance under the Hart-Scott-Rodino Act.</li>
</ul>
<ul class="wp-block-list">
<li>Scopely has officially completed its $3.5 billion acquisition of Niantic's games business, according <a href="https://mobilegamer.biz/the-3-5bn-scopely-niantic-deal-has-officially-closed/">to</a> Mobile Gamer. The deal brings in over 400 new staff and a blockbuster portfolio that includes &#8220;Pokémon Go&#8221; and Wayfarer apps. The acquired titles collectively attracted more than 30 million monthly active users and generated over $1 billion in revenue last year. Announcing the deal&#8217;s close on May 29, Scopely emphasized its commitment to continuity, stating that longtime Niantic leaders Kei Kawai and Ed Wu will continue to lead the game teams, ensuring stability for Pokémon fans and other titles. Niantic's remaining titles, &#8220;Ingress&#8221; and &#8220;Peridot,&#8221; will remain under the newly formed Niantic Spatial, still led by CEO John Hanke. Scopely's co-CEOs hinted at more acquisitions ahead, noting they evaluated over 800 companies last year.</li>
</ul>
<h3 class="wp-block-heading">Bankruptcy Block</h3>
<ul class="wp-block-list">
<li>At Home, a home-goods retailer owned by private equity firm Hellman &amp; Friedman, is preparing to file for Chapter 11 bankruptcy. Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-05-27/retailer-at-home-prepares-to-file-for-bankruptcy-in-coming-weeks?sref=TBDibEcD">reported</a> that the company did not make its interest payment on May 15 and entered a forbearance pact with lenders on May 23, citing sources. The reprieve runs through June 30,</li>
</ul>
<ul class="wp-block-list">
<li>All 500 hand-scooped Thrifty Ice Cream counters inside Rite Aid locations are set to close. The beloved brand, founded in 1940, will still be available at some standalone shops and retailers. Rite Aid, which acquired the brand in 1996 and proudly served its signature cylindrical scoops across the West Coast, is now scooping out hundreds of store closures and looking to sell off assets as part of a <a href="https://abc7ny.com/post/rite-aid-stores-closing-drug-store-chain-close-300-more-locations-amid-bankruptcy/16588893/">bankruptcy</a> process, including Thrifty and its El Monte, California-based factory.</li>
</ul>
<ul class="wp-block-list">
<li>Everstream, a business-only fiber network, is selling most of its operations to stalking horse bidder Bluebird Fiber as part of a Chapter 11 bankruptcy auction. This follows earlier sales of its Illinois and St. Louis networks and plans to exit Pennsylvania. The sale to Bluebird includes most assets and comes with a $55 million lifeline in debtor-in-possession financing. Everstream remains open to better offers.</li>
</ul>
<h3 class="wp-block-heading">Notes From The Block</h3>
New data suggests that, after several volatile years, the behavioral health sector is regaining favor among strategic and financial buyers.
In the first quarter, 47 transactions were reported, including 34 mergers and acquisitions. That&#8217;s the highest M&amp;A volume since the fourth quarter of 2022, according to investment banker Kevin Taggart.
In <a href="https://www.mertztaggart.com/post/q1-2025-behavioral-health-m-a-report">a blog post</a> published this week, Taggart explained that renewed interest in the intellectual and developmental disabilities (I/DD) and autism segments was a key driver of the momentum. The firm tallied 12 transactions in Q1, the highest level since 2021.
Applied behavior analysis (ABA) therapy providers, in particular, are back in high demand. 
"The dust has seemed to settle" following the pandemic-era wage inflation and a wave of bankruptcies among large ABA providers, Taggart, a managing partner at Mertz Taggart, wrote. That shift has led to heightened buyer interest, especially in the wake of major exits.
The mental health subsector continues to show strong and steady deal flow, too. Twenty-nine transactions (19 M&amp;A and 10 growth investments) were announced in Q1, roughly matching the 30 deals reported in Q4 2024. 
Demand for psychiatric hospitals is particularly robust, though limited supply constrains deal volume. "We've had more groups ask us for psych hospitals since Q1 this year than probably any quarter in the last three or four years," Taggart said. "But there are fewer smaller operators out there."
Taggart also pointed to an ongoing trend: sustained investor appetite for high-valuation growth deals. "Money has continued to pour into these growth deals, which surprised us a bit," he said, signaling continued bullish sentiment across behavioral health verticals.
<a href="https://www.benzinga.com/top-stories/25/05/45593861/deal-dispatch-onlyfans-to-sell-for-8-billion-telecom-ma-heats-up-wolfspeed-on-road-to-bankruptcy">For last week&#8217;s edition of the Deal Dispatch, click here</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/05/45697983/consumer-sentiment-stuck-at-3-year-lows-as-inflation-fears-hit-44-year-high">Consumer Sentiment Stuck At 3-Year Lows As Inflation Fears Hit 44-Year High</a></li>
</ul>
Image created using a photo from Shutterstock

Gaming

ETWO

Deal Dispatch: Beauty Brand Seeks Pretty Price Tag, Behavioral Health Firms Hit Auction Block

Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Hologic and provided 12-month price targets. The average target is $68.0, accompanied by a high estimate of $71.00 and a low estimate of $62.00. This current average has decreased by 12.07% from the previous average price target of $77.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1748433616_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Hologic by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$65.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$70.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$71.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$62.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hologic. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hologic compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Hologic's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Hologic's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HOLX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Hologic analyst ratings.</a>
<h2>About Hologic</h2>
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
<h3>Hologic: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Hologic's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -1.23%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Hologic's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -1.73%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Hologic's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -0.37%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.2%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Hologic's debt-to-equity ratio is below the industry average. With a ratio of 0.55, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 6 Analyst Projections For Hologic

Needham analyst Mike Matson reiterates Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Hologicto Hold

Private equity firms TPG and Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) recently bid to acquire Hologic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>), valuing the U.S. medical technology company at over $16 billion.
Hologic is an American medical technology company primarily focused on women&#8217;s health. It sells medical devices for diagnostics, <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">surgery, and imaging</a>.
While Hologic rejected the initial nonbinding offer, citing sources, the Financial Times writes that the negotiations could resume.
Benzinga reached out to Hologic for comments.
Also Read: <a href="https://www.benzinga.com/general/health-care/25/01/43065688/fda-warns-hologic-over-biozorb-manufacturing-violations" target="_blank" rel="noreferrer noopener">FDA Warns Hologic Over BioZorb Manufacturing Violations</a>
The proposed buyout valued Hologic between $16.3 billion and $16.7 billion, including debt, and would have priced shares at $70 to $72—well above the company&#8217;s closing price of $54.28 on Friday.
The FT report adds that if successful, the deal would have ranked among the largest leveraged buyouts of the year.
Despite the generous premium, Hologic declined the approach. Its stock has dropped about 24% this year, weighed down by U.S. tariffs and softening demand.
Hologic reported adjusted earnings of $1.03 per share for the second quarter of 2025, the same as last year, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $1.02</a>. Sales decreased 1.2% year over year to $1.05 billion, beating the <a href="https://www.benzinga.com/pressreleases/25/05/b45149552/hologic-announces-financial-results-for-second-quarter-of-fiscal-2025" target="_blank" rel="noreferrer noopener">consensus of $1 billion</a>.
Hologic lowered fiscal 2025 adjusted earnings per share guidance from $4.25-4.35 to $4.15-4.25 compared to consensus of $4.26, based on tariffs and geopolitical conditions.
The company reaffirmed sales guidance of $4.05 billion-$4.10 billion compared to the consensus of $4.08 billion.
Hologic expects third-quarter adjusted earnings of $1.04-1.07 per share versus consensus of $1.10 and sales of $1 billion-1.01 billion compared to the consensus of $1.03 billion.
The FT report <a target="_blank" href="https://www.ft.com/content/f4d12c75-1a54-4d8c-8aa6-f863cbdc4aab" rel="noreferrer noopener">noted</a> that CEO MacMillan acknowledged in the company&#8217;s recent quarterly earnings call that the business had endured &#8220;a tumultuous few months from a macroeconomic and policy perspective.&#8221; Still, it emphasized that the firm is making progress.
Hologic has long been viewed as a possible takeover target. Activist investor Carl Icahn acquired a 12.5% stake in 2013, prompting the company to adopt a poison pill strategy. Icahn later secured two board seats and influenced leadership changes, including Steve MacMillan&#8217;s appointment as CEO.
Price Action: HOLX stock is up 15.1% at $62.48 at the last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids" target="_blank" rel="noreferrer noopener">Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For &#8216;Healthy&#8217; Pregnant Women, Children</a></li>
</ul>

Health Care

Rumors

Media

General

Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?

Wall Street charged higher Tuesday, with U.S. equities posting broad-based gains by midday as investors embraced a risk-on mood, spurred by easing Treasury yields and renewed optimism surrounding trade talks between the U.S. and the European Union.
The bond market drove a major sentiment shift. U.S. 30-year Treasury yields sank 10 basis points to 4.93%, falling below the psychologically key 5% threshold for the first time in days. 
The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) rallied 1.5%, eyeing the strongest daily gain since late February 2025. 
This move follows a surprise development in Japan, where the Ministry of Finance announced a reduction in the issuance of longer-dated government bonds. That decision triggered an 18-basis-point drop in Japan's 30-year yield, creating a ripple effect that eased pressure across global fixed-income markets.
The sharp decline in yields helped equities rally across the board. The S&amp;P 500 rose 1.9%, extending May&#8217;s gains to more than 6%. The benchmark is now tracking its strongest monthly performance since November 2023.
Technology and small-cap stocks outpaced broader benchmarks, adding momentum to the rally. Every sector in the S&amp;P 500 traded higher on the day. 
Among the mega-caps, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) stood out with a 6.4% gain, reclaiming price levels last seen in mid-February. 
As equity and bond sentiment improved, traditional safe-haven assets lost appeal. Gold prices fell 1%, slipping below $3,300 per ounce. The move reflects investors rotating out of defensive plays amid increasing appetite for risk.
In energy markets, crude oil dropped 1.5% to $60.50 a barrel, while copper prices slid 2.1%, signaling some caution in industrial demand despite the bullish tone in equities.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) traded near $110,000, remaining close to its all-time highs. 
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S/ Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day chg. %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,406.38</td>
<td>2.3%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,085.63</td>
<td>2.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,913.36</td>
<td>1.9%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,271.70</td>
<td>1.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 1:15 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rallied 1.9% to $590.07.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 1.6% to $422.83.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;soared 2.3% to $520.83.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 2.3% to $207.26.</li>
<li>The&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 2.8%; the&nbsp;Consumer&nbsp;Staples Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) lagged, up 0.5%. </li>
</ul>
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
<ul class="wp-block-list">
<li>Hologic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) jumped 12.7%, paring earlier bigger gains, after the company rejected a non-binding takeover bid worth up to $16.7 billion from private equity firms TPG Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) and Blackstone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>).</li>
<li>PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) tumbled 15% after reporting weaker-than-expected quarterly earnings. </li>
<li>The S&amp;P 500&#8216;s top performers during Tuesday&#8217;s New York session included Hologic Inc., up 14.93%; Tesla Inc., which gained 6.87%; Deckers Outdoor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>), rising 6.82%; Royal Caribbean Cruises Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>), up 6.66% and Warner Bros. Discovery Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>), climbing 6.61%.</li>
<li>The biggest laggards included Fair Isaac Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>), which sank 9.63%; AutoZone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) down 4.55%; VeriSign Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>) losing 4.28%; Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) slipping 1.70% and Copart Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) falling 1.68%.</li>
<li>
<path fill-rule="evenodd" clip-rule="evenodd" d="M7 5C7 3.34315 8.34315 2 10 2H19C20.6569 2 22 3.34315 22 5V14C22 15.6569 20.6569 17 19 17H17V19C17 20.6569 15.6569 22 14 22H5C3.34315 22 2 20.6569 2 19V10C2 8.34315 3.34315 7 5 7H7V5ZM9 7H14C15.6569 7 17 8.34315 17 10V15H19C19.5523 15 20 14.5523 20 14V5C20 4.44772 19.5523 4 19 4H10C9.44772 4 9 4.44772 9 5V7ZM5 9C4.44772 9 4 9.44772 4 10V19C4 19.5523 4.44772 20 5 20H14C14.5523 20 15 19.5523 15 19V10C15 9.44772 14.5523 9 14 9H5Z" fill="currentColor"></path>
<path fill-rule="evenodd" clip-rule="evenodd" d="M12.1318 2.50389C12.3321 2.15338 12.7235 1.95768 13.124 2.00775L13.5778 2.06447C16.0449 2.37286 17.636 4.83353 16.9048 7.20993L16.354 8.99999H17.0722C19.7097 8.99999 21.6253 11.5079 20.9313 14.0525L19.5677 19.0525C19.0931 20.7927 17.5124 22 15.7086 22H6C4.34315 22 3 20.6568 3 19V12C3 10.3431 4.34315 8.99999 6 8.99999H8C8.25952 8.99999 8.49914 8.86094 8.6279 8.63561L12.1318 2.50389ZM10 20H15.7086C16.6105 20 17.4008 19.3964 17.6381 18.5262L19.0018 13.5262C19.3488 12.2539 18.391 11 17.0722 11H15C14.6827 11 14.3841 10.8494 14.1956 10.5941C14.0071 10.3388 13.9509 10.0092 14.0442 9.70591L14.9932 6.62175C15.3384 5.49984 14.6484 4.34036 13.5319 4.08468L10.3644 9.62789C10.0522 10.1742 9.56691 10.5859 9 10.8098V19C9 19.5523 9.44772 20 10 20ZM7 11V19C7 19.3506 7.06015 19.6872 7.17071 20H6C5.44772 20 5 19.5523 5 19V12C5 11.4477 5.44772 11 6 11H7Z" fill="currentColor"></path>
<path fill-rule="evenodd" clip-rule="evenodd" d="M11.8727 21.4961C11.6725 21.8466 11.2811 22.0423 10.8805 21.9922L10.4267 21.9355C7.95958 21.6271 6.36855 19.1665 7.09975 16.7901L7.65054 15H6.93226C4.29476 15 2.37923 12.4921 3.0732 9.94753L4.43684 4.94753C4.91145 3.20728 6.49209 2 8.29589 2H18.0045C19.6614 2 21.0045 3.34315 21.0045 5V12C21.0045 13.6569 19.6614 15 18.0045 15H16.0045C15.745 15 15.5054 15.1391 15.3766 15.3644L11.8727 21.4961ZM14.0045 4H8.29589C7.39399 4 6.60367 4.60364 6.36637 5.47376L5.00273 10.4738C4.65574 11.746 5.61351 13 6.93226 13H9.00451C9.32185 13 9.62036 13.1506 9.8089 13.4059C9.99743 13.6612 10.0536 13.9908 9.96028 14.2941L9.01131 17.3782C8.6661 18.5002 9.35608 19.6596 10.4726 19.9153L13.6401 14.3721C13.9523 13.8258 14.4376 13.4141 15.0045 13.1902V5C15.0045 4.44772 14.5568 4 14.0045 4ZM17.0045 13V5C17.0045 4.64937 16.9444 4.31278 16.8338 4H18.0045C18.5568 4 19.0045 4.44772 19.0045 5V12C19.0045 12.5523 18.5568 13 18.0045 13H17.0045Z" fill="currentColor"></path>
<path fill-rule="evenodd" clip-rule="evenodd" d="M11 4.9099C11 4.47485 10.4828 4.24734 10.1621 4.54132L6.67572 7.7372C6.49129 7.90626 6.25019 8.00005 6 8.00005H4C3.44772 8.00005 3 8.44776 3 9.00005V15C3 15.5523 3.44772 16 4 16H6C6.25019 16 6.49129 16.0938 6.67572 16.2629L10.1621 19.4588C10.4828 19.7527 11 19.5252 11 19.0902V4.9099ZM8.81069 3.06701C10.4142 1.59714 13 2.73463 13 4.9099V19.0902C13 21.2655 10.4142 22.403 8.81069 20.9331L5.61102 18H4C2.34315 18 1 16.6569 1 15V9.00005C1 7.34319 2.34315 6.00005 4 6.00005H5.61102L8.81069 3.06701ZM20.3166 6.35665C20.8019 6.09313 21.409 6.27296 21.6725 6.75833C22.5191 8.3176 22.9996 10.1042 22.9996 12.0001C22.9996 13.8507 22.5418 15.5974 21.7323 17.1302C21.4744 17.6185 20.8695 17.8054 20.3811 17.5475C19.8927 17.2896 19.7059 16.6846 19.9638 16.1962C20.6249 14.9444 20.9996 13.5175 20.9996 12.0001C20.9996 10.4458 20.6064 8.98627 19.9149 7.71262C19.6514 7.22726 19.8312 6.62017 20.3166 6.35665ZM15.7994 7.90049C16.241 7.5688 16.8679 7.65789 17.1995 8.09947C18.0156 9.18593 18.4996 10.5379 18.4996 12.0001C18.4996 13.3127 18.1094 14.5372 17.4385 15.5604C17.1357 16.0222 16.5158 16.1511 16.0539 15.8483C15.5921 15.5455 15.4632 14.9255 15.766 14.4637C16.2298 13.7564 16.4996 12.9113 16.4996 12.0001C16.4996 10.9859 16.1653 10.0526 15.6004 9.30063C15.2687 8.85905 15.3578 8.23218 15.7994 7.90049Z" fill="currentColor"></path>
<path d="M2.5 5.5C4.3 5.2 5.2 4 5.5 2.5C5.8 4 6.7 5.2 8.5 5.5C6.7 5.8 5.8 7 5.5 8.5C5.2 7 4.3 5.8 2.5 5.5Z" fill="currentColor" stroke="currentColor" stroke-linecap="round" stroke-linejoin="round"></path>
<path d="M5.66282 16.5231L5.18413 19.3952C5.12203 19.7678 5.09098 19.9541 5.14876 20.0888C5.19933 20.2067 5.29328 20.3007 5.41118 20.3512C5.54589 20.409 5.73218 20.378 6.10476 20.3159L8.97693 19.8372C9.72813 19.712 10.1037 19.6494 10.4542 19.521C10.7652 19.407 11.0608 19.2549 11.3343 19.068C11.6425 18.8575 11.9118 18.5882 12.4503 18.0497L20 10.5C21.3807 9.11929 21.3807 6.88071 20 5.5C18.6193 4.11929 16.3807 4.11929 15 5.5L7.45026 13.0497C6.91175 13.5882 6.6425 13.8575 6.43197 14.1657C6.24513 14.4392 6.09299 14.7348 5.97903 15.0458C5.85062 15.3963 5.78802 15.7719 5.66282 16.5231Z" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"></path>
<path d="M14.5 7L18.5 11" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"></path>
<div class="text-center"></div>
<path d="M7.5 13.25C7.98703 13.25 8.45082 13.1505 8.87217 12.9708C8.46129 14.0478 7.62459 15.5792 6.35846 15.76C5.81173 15.8382 5.43183 16.3447 5.50993 16.8914C5.58804 17.4382 6.09457 17.8181 6.6413 17.7399C9.19413 17.3753 10.7256 14.4711 11.169 12.1909C11.4118 10.942 11.3856 9.58095 10.8491 8.44726C10.2424 7.16517 8.92256 6.24402 7.48508 6.25001C5.55895 6.25805 4 7.82196 4 9.74998C4 11.683 5.567 13.25 7.5 13.25Z" fill="currentColor"></path>
<path d="M16.18 13.25C16.667 13.25 17.1308 13.1505 17.5522 12.9708C17.1413 14.0478 16.3046 15.5792 15.0385 15.76C14.4917 15.8382 14.1118 16.3447 14.1899 16.8914C14.268 17.4382 14.7746 17.8181 15.3213 17.7399C17.8741 17.3753 19.4056 14.4711 19.849 12.1909C20.0918 10.942 20.0656 9.58095 19.5291 8.44726C18.9224 7.16517 17.6026 6.24402 16.1651 6.25001C14.2389 6.25805 12.68 7.82196 12.68 9.74998C12.68 11.683 14.247 13.25 16.18 13.25Z" fill="currentColor"></path>
<div aria-hidden="true" data-edge="true" class="pointer-events-none h-px w-px"></div>
Stocks slated to report earnings after the close include OKTA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) and Heico Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>). Read Now: • <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45616116/trumps-tariffs-may-trigger-an-inflation-shock-but-not-a-lasting-one-goldman-sachs-says">Trump&#8217;s Tariffs May Trigger An Inflation Shock &#8211; But Not A Lasting One, Goldman Sachs Says</a> Photo: Shutterstock</li>
</ul>

Equities

Government

Macro Economic Events

Mid Cap

Regulations

Bonds

Broad U.S. Equity ETFs

Treasuries

Global

Econ #s

Economics

Tech

ETFs

$BTC

CPRT

DECK

SPDR Dow Jones Industrial Average ETF Trust

FICO

OKTA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

iShares Trust Barclays 20+ Year Treasury Bond Fund

TSLA

VRSN

Select Sector SPDR-Consumer Discretionary

Wall Street Rockets As Bond Yields Drop, Tesla Hits 3-Month Highs: What's Driving Markets Tuesday?

Hologic Shares Resume Trade

Hologic Shares Halted On Circuit Breaker To The Upside, Stock Now Up 7.24%

<a href="https://www.ft.com/content/f4d12c75-1a54-4d8c-8aa6-f863cbdc4aab" title="https://www.ft.com/content/f4d12c75-1a54-4d8c-8aa6-f863cbdc4aab">https://www.ft.com/content/f4d12c75-1a54-4d8c-8aa6-f863cbdc4aab</a>

'TPG and Blackstone offered $16B to take health group Hologic private' - Financial Times

Completed assessment of more than 2,800 patients highlights the profound impact of the test in helping to predict the likelihood of extended endocrine therapy benefit for patients with HR+ breast cancer to support more informed care decisions
Hologic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) and its subsidiary, Biotheranostics, Inc., today announced new data demonstrating the significant clinical impact of the Breast Cancer Index&#xAE; (BCI&#xAE;) test, which will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2025.

Biotech

Hologic And Biotheranostics To Present New Data At ASCO 2025 Highlighting Breast Cancer Index Test's Impact In Guiding Extended Endocrine Therapy Decisions For Over 2,800 HR+ Breast Cancer Patients

Hologic's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NYSE">HOLX</a>) short percent of float has fallen 20.1% since its last report. The company recently reported that it has 5.35 million shares sold short, which is 3.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.05 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Hologic Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747922441_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Hologic has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Hologic's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Hologic's peer group average for short interest as a percentage of float is 4.11%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Stephens &amp; Co. analyst Mason Carrico maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Overweight and lowers the price target from $77 to $70.

Stephens & Co. Maintains Overweight on Hologic, Lowers Price Target to $70

In the current market session, Hologic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) price is at $54.19, after a 0.06% increase. However, over the past month, the stock fell by 9.41%, and in the past year, by 30.41%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1746464421_0.png" alt="Past Year Chart" />

<h3>Evaluating Hologic P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 57.63 in the Health Care Equipment &amp; Supplies industry, Hologic Inc. has a lower P/E ratio of 22.76. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1746464421_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Hologic

Morgan Stanley analyst Tejas Savant maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Equal-Weight and lowers the price target from $77 to $65.

Morgan Stanley Maintains Equal-Weight on Hologic, Lowers Price Target to $65

In the preceding three months, 10 analysts have released ratings for Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.0, a high estimate of $90.00, and a low estimate of $62.00. A decline of 6.44% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1746219706_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Hologic by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$70.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$71.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$62.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$85.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$73.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hologic. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hologic compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Hologic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Hologic's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HOLX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Hologic analyst ratings.</a>
<h2>Delving into Hologic's Background</h2>
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
<h3>Financial Milestones: Hologic's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Hologic showcased positive performance, achieving a revenue growth rate of 0.86% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Hologic's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 19.67%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.06%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Hologic's ROA excels beyond industry benchmarks, reaching 2.25%. This signifies efficient management of assets and strong financial health.
Debt Management: Hologic's debt-to-equity ratio is below the industry average at 0.53, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Hologic: 10 Analysts Share Their Views

Press Releases

Hologic Announces Financial Results for First Quarter of Fiscal 2025

Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay

Hologic to Webcast Presentation at the Raymond James 46th Annual Institutional Investors Conference

Hologic to Announce Financial Results for the Second Quarter of Fiscal 2025 on Thursday, May 1, 2025

Wayde McMillan Elected to Hologic Board of Directors

Hologic Details Environmental, Social and Governance Efforts — Including Expanded Environmental Ambitions — in New Sustainability Report

Groundbreaking New Data on Hologic's AI-Powered Mammography Technology to Be Presented at SBI

Hologic Announces Financial Results for Second Quarter of Fiscal 2025

Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients

Comments

Hologic

Vendite allo scoperto

Hologic (NASDAQ:HOLX) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO